Gastroesophageal reflux disease in primary care in the light of current guidelines Review article
Article Sidebar
Published:
Jun 30, 2025
Keywords:
gastroesophageal reflux disease, endoscopic diagnosis, red flag symptoms, proton pump inhibitors
Main Article Content
Abstract
Gastroesophageal reflux disease is frequent, recurrent disease. Clinical manifestations are various, with typical esophageal or extraesophageal symptoms. Endoscopical diagnosis is necessary in case of alarm symptoms, in elderly patients and before the surgical treatment. Proton pump inhibitors are fundamental in medical treatment.
Article Details
How to Cite
Skrzydło-Radomańska, B. (2025). Gastroesophageal reflux disease in primary care in the light of current guidelines. Medycyna Faktow (J EBM), 18(2(67), 176-180. https://doi.org/10.24292/01.MF.0225.02
Issue
Section
Articles
Copyright © by Medical Education. All rights reserved.
References
1. Vakil N, van Zanten SV, Kahrilas P et al. Global Consensus Grup. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006; 101(8): 1900-43.
2. Zhang D, Liu S, Li Z et al. Global, regional and national burden of gastroesophageal reflux disease, 1990-2019: update from the GBD study. Ann Med. 2022; 54(1): 1372-84.
3. Świdnicka-Siergiejko A, Marek T, Waśko-Czopnik D et al. Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology. Pol Arch Intern Med. 2022; 132(2): 16196.
4. Kuźlik-Gołębiowska K, Rydzewska G. Co zmieniły wytyczne PTGE w leczeniu choroby refluksowej żołądkowo-przełykowej? Terapia. 2022; 9: 4-10.
5. Waśko-Czopnik D, Gąsiorowska A, Janiak M et al. Rekomendacje dla lekarzy rodzinnych dotyczące diagnostyki I leczenia choroby refluksowej przełyku. Lekarz POZ. 2024; 4: 190-201.
6. Gyawali CP, Yadlapati R, Fass R et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 2024; 73: 361-71.
7. Katz PO, Dunbar KB, Schnoll-Sussman FH et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022; 117: 27-56.
8. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999; 45: 172-80.
9. Waśko-Czopnik D, Wiatrak B. The efficacy and safety of itopride as an add-ontherapy to a proton pump inhibitorin the treatment of gastroesophageal reflux disease. Gastroenterol Rev. 2023; 19: 60-5.
2. Zhang D, Liu S, Li Z et al. Global, regional and national burden of gastroesophageal reflux disease, 1990-2019: update from the GBD study. Ann Med. 2022; 54(1): 1372-84.
3. Świdnicka-Siergiejko A, Marek T, Waśko-Czopnik D et al. Diagnostic and therapeutic management in gastroesophageal reflux disease: consensus of the Polish Society of Gastroenterology. Pol Arch Intern Med. 2022; 132(2): 16196.
4. Kuźlik-Gołębiowska K, Rydzewska G. Co zmieniły wytyczne PTGE w leczeniu choroby refluksowej żołądkowo-przełykowej? Terapia. 2022; 9: 4-10.
5. Waśko-Czopnik D, Gąsiorowska A, Janiak M et al. Rekomendacje dla lekarzy rodzinnych dotyczące diagnostyki I leczenia choroby refluksowej przełyku. Lekarz POZ. 2024; 4: 190-201.
6. Gyawali CP, Yadlapati R, Fass R et al. Updates to the modern diagnosis of GERD: Lyon consensus 2.0. Gut. 2024; 73: 361-71.
7. Katz PO, Dunbar KB, Schnoll-Sussman FH et al. ACG clinical guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022; 117: 27-56.
8. Lundell LR, Dent J, Bennett JR et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut. 1999; 45: 172-80.
9. Waśko-Czopnik D, Wiatrak B. The efficacy and safety of itopride as an add-ontherapy to a proton pump inhibitorin the treatment of gastroesophageal reflux disease. Gastroenterol Rev. 2023; 19: 60-5.